Identification of serum biomarker signatures associated with pancreatic cancer

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Identification of serum biomarker signatures associated with pancreatic cancer. / Wingren, Christer; Sandström Gerdtsson, Anna; Segersvard, R.; Carlsson, Anders; Andersson, Roland; Lohr, M.; Borrebaeck, Carl.

I: Cancer Research, Vol. 72, 2012, s. 2481-90.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Wingren, Christer ; Sandström Gerdtsson, Anna ; Segersvard, R. ; Carlsson, Anders ; Andersson, Roland ; Lohr, M. ; Borrebaeck, Carl. / Identification of serum biomarker signatures associated with pancreatic cancer. I: Cancer Research. 2012 ; Vol. 72. s. 2481-90.

RIS

TY - JOUR

T1 - Identification of serum biomarker signatures associated with pancreatic cancer

AU - Wingren, Christer

AU - Sandström Gerdtsson, Anna

AU - Segersvard, R.

AU - Carlsson, Anders

AU - Andersson, Roland

AU - Lohr, M.

AU - Borrebaeck, Carl

N1 - 10

PY - 2012

Y1 - 2012

N2 - Pancreatic cancer is an aggressive disease with poor prognosis, due, in part, to the lack of disease-specific biomarkers that could afford early and accurate diagnosis. With a recombinant antibody microarray platform, targeting mainly immunoregulatory proteins, we screened sera from 148 patients with pancreatic cancer, chronic pancreatitis, autoimmune pancreatitis (AIP), and healthy controls (N). Serum biomarker signatures were derived from training cohorts and the predictive power was evaluated using independent test cohorts. The results identified serum portraits distinguishing pancreatic cancer from N [receiver operating characteristics area under the curve (AUC) of 0.95], chronic pancreatitis (0.86), and AIP (0.99). Importantly, a 25-serum biomarker signature discriminating pancreatic cancer from the combined group of N, chronic pancreatitis, and AIP was determined. This signature exhibited a high diagnostic potential (AUC of 0.88). In summary, we present the first prevalidated, multiplexed serum biomarker signature for diagnosis of pancreatic cancer that may improve diagnosis and prevention in premalignant diseases and in screening of high-risk individuals.

AB - Pancreatic cancer is an aggressive disease with poor prognosis, due, in part, to the lack of disease-specific biomarkers that could afford early and accurate diagnosis. With a recombinant antibody microarray platform, targeting mainly immunoregulatory proteins, we screened sera from 148 patients with pancreatic cancer, chronic pancreatitis, autoimmune pancreatitis (AIP), and healthy controls (N). Serum biomarker signatures were derived from training cohorts and the predictive power was evaluated using independent test cohorts. The results identified serum portraits distinguishing pancreatic cancer from N [receiver operating characteristics area under the curve (AUC) of 0.95], chronic pancreatitis (0.86), and AIP (0.99). Importantly, a 25-serum biomarker signature discriminating pancreatic cancer from the combined group of N, chronic pancreatitis, and AIP was determined. This signature exhibited a high diagnostic potential (AUC of 0.88). In summary, we present the first prevalidated, multiplexed serum biomarker signature for diagnosis of pancreatic cancer that may improve diagnosis and prevention in premalignant diseases and in screening of high-risk individuals.

KW - Pancreatic Neoplasms/blood

KW - Middle Aged

KW - Humans

KW - Pancreatic Ductal/blood

KW - Carcinoma

KW - Biological Markers/blood

KW - 80 and over

KW - Aged

KW - Adolescent

KW - Adult

KW - Pancreatitis/diagnosis

KW - Pancreatitis

KW - Chronic/blood

KW - Tumor Markers

KW - Biological/blood

U2 - 10.1158/0008-5472.CAN-11-2883

DO - 10.1158/0008-5472.CAN-11-2883

M3 - Article

VL - 72

SP - 2481

EP - 2490

JO - Cancer research. Supplement

T2 - Cancer research. Supplement

JF - Cancer research. Supplement

SN - 1538-7445

ER -